I’d like to say I understand the stock market, but sadly, I must admit that I don’t. I live in a world where good news is good, but that clearly is not the case in the financial sector. It seems that where investors are concerned, good news is sometimes not good enough. Despite the fact that Altus Pharmaceuticals reported positive preliminary results from its phase III clinical trial of a pancreatic enzyme called Trizytec, Altus stock tanked to an all-time low last week. The preliminary results of the Trizytec trial showed that it improved fat and protein absorption, but the improvements were not as significant as investors had hoped they would be.
Personally, I’m pretty pleased with the results. Trizytek is the first pancreatic enzyme that is not made from the pancreas of pigs, which would be a blessing for many people with cystic fibrosis who must take enzymes to prevent malnutrition but cannot tolerate, or choose not to consume pork products. Even if Trizytek cannot perform better than products already on the market, it certainly would provide an equivalent option for treatment that no other product can offer. Where’s the bad news in that, Wall Street?
Read more about preventing malnutrition in people with cystic fibrosis.